^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + Tafinlar (dabrafenib) (BRAF inhibitor) + Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
Published date:
07/12/2020
Excerpt:
The overall response rate (ORR) was 69.2% (95% CI: 48.2–85.7), corresponding to 18 patients…The OS rate at 12 months was 76% (95% CI: 54–88)….the triplet combination of dabrafenib, trametinib, and durvalumab is feasible in patients with BRAF-mutant advanced melanoma...
DOI:
doi.org/10.1038/s41467-020-19810-w
Trial ID:
